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Dr Thomas A. D’Amico (Durham, NC). Dr Freeman, I con-
gratulate you and your colleagues on performing this important
study. Improving the quality of care in the setting of the treatment
of lung cancer should be the most important goal of future systems
of care for cancer, because lung cancer is responsible for more than
a third of all cancer deaths. Adherence to established guidelines,
such as the NCCN guidelines, is the most efficient pathway to
the improvement of outcomes. These guidelines in fact specify
that patients with lung cancer should be treated by lung cancer spe-
cialists; that is, thoracic surgeons. Sadly, that recommendation has
not reached the standard of care status in the United States.
This study, an analysis of more than 6400 patients in a single
health care system, provides more evidence to support the NCCN’s
recommendations. Patients operated on by thoracic surgeons had
significantly lower morbidity and mortality and also shorter stay
despite being older and having a higher Charlson comorbidity in-
dex than patients operated on by general surgeons. As well, pa-
tients whose disease was staged and managed by thoracic
surgeons received better evidence-based care, including preopera-
tive and intraoperative mediastinal staging, all at a lower cost. Al-
though there are acknowledged limitations of an administrative
database analysis, as you outlined, the findings are persuasive;
however, we are not the ones needing persuasion.
Although we would all agree that thoracic surgeons provide su-
perior lung cancer care, does your research indicate that there were
in fact thoracic surgeons whowere not providing quality evidence-
based care in this particular health care system? We will not be
successful in changing paradigms of care if we are seen to be pro-
tecting inferior thoracic surgeons. Analysis of outcomes in the
general thoracic surgery Society of Thoracic Surgeons databaseThe Journal of Thoracic and Csuggests that quality of lung cancer care is not universal in that
database.
Dr Freeman. We were not, by agreement, able to focus on in-
dividual provider results with the health system. So I cannot tell
you Dr X’s mortality versus Dr Y’s, and that was by design.
Dr D’Amico. So you will be seen as protecting inferior thoracic
surgeons. The NCCN guidelines chosen for this study included the
use of computed tomographic scanning and pulmonary function
testing, relatively low thresholds for quality and nearly universally
used by general and thoracic surgeons alike. Are there other pa-
rameters that you could have used or would use in the future to dif-
ferentiate adherence to evidence-based guidelines more
discriminatingly?
Dr Freeman. There certainly are other factors we could use. As
you know, the hardest part of a study like this is not what to include
but what not to include, because it has to be manageable. We chose
what we thought were fairly low bar measures, such as pulmonary
function tests, computed tomographic scan, and staging the medi-
astinum. We gave credit for positron emission tomography and
mediastinoscopy. So we set the bar pretty low intentionally, as
the first step. There are much more complex measures that we
could use, and that may be something to look at in the future.
Dr D’Amico. Can you name what these measures are? What
would you study to actually differentiate quality from not quality
in the future?
Dr Freeman. One of the things I think is important personally,
which is almost impossible to measure, unfortunately, is multidis-
ciplinary care and multidisciplinary care conference planning. We
found that to be extremely effective; transparency, multiple heads
put around the table. It’s very hard to measure though.
Dr D’Amico. Finally, what processes do you recommend to as-
certain that only qualified surgeons are credentialed to manage pa-
tients with lung cancer in the future?
Dr Freeman. Well, I’m the eternal pessimist, so I have con-
cerns that we as a physician group will ever be able to do that.
One of the reasons we included cost in this and one of the reasons
that we looked at a single health system is because I think the
health system eventually will say, ‘‘Here are some data. Show us
that you did additional training to do this procedure or you
shouldn’t be doing it.’’ So I think it will have to be an external locus
of control.
Dr D’Amico. Good paper. Thank you.
Dr Tomasz Grodzki (Szczecin, Poland). I congratulate you.
I also have a short comment. I come from a country where the hos-
pital charge for a lobectomy is US $5000, and mortality and mor-
bidity are exactly the same. The answer is because we convinced
general surgeons in Poland that it’s so complicated and dangerous
to perform lobectomy that they are doing nothing, and 99% of lo-
bectomies in Poland are performed by certified thoracic surgeons.
This is the direction this Society should promote. It’s simply dan-
gerous to refer patients to general surgeons for lobectomy. If we
compare it with the previous lecture by David Jones’s group that
the number of lung cancer cases in teaching hospitals is going
down, the Society should fight for protecting the patients first
and providing the patients with thoracic surgeons second. I think
that the government relations committee or any of the Society
committees should promote these results, because it’s simply ben-
eficial for the patients.ardiovascular Surgery c Volume 145, Number 1 73
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SDr Freeman. Obviously, I agree in principle with your com-
ments. As Dr Krasna would probably tell you, there are a lot of di-
lemmas regarding that kind of an idea. With 85% of cancer care in
the United States occurring outside a National Cancer Institute
cancer center, outside a university system, and geographically
I’m not sure how you would make that work, but I think in princi-
ple you have a valid point.
Dr Mark J. Krasna (Neptune, NJ). Rich, I think it was a great
study. What I enjoyed, kind of looking at this as the other side of
the good paper we heard this morning from UVA, is that since it
was all one health system, although you did blind some of the is-
sues that Tommy and I would have liked to have seen, you really
took a deep dive into the data. So I’ll just ask you the dirty ques-
tion, which is, if you were the vice president of quality assurance
of your health system, why is it when you’re looking at the health
system that so many lobectomies are being done for cancer by
non–board certified thoracic surgeons, when in your health system
you actually have a built-in referral opportunity to actually region-
alize, which most of the hospitals don’t even have that opportunity
across the states?
Dr Freeman. I think it’s multifactorial. Access is an issue. Yes,
there are 76 hospitals in our system. Some are in Idaho, and some
are in Indiana, and some are in Wisconsin. When you look at non-
cardiac thoracic surgeons in 76 hospitals, there are really 4 prac-
tices that have dedicated general thoracic surgeons. The vast
majority of this practice is done by cardiothoracic surgeons. One
thing that I do want to continue to look at and do some subset anal-
ysis on is the size of the hospital and who does the lobectomy. It’s
intuitive, but it’s a general surgeon in a small hospital. Often it’s
not by choice. Often, when I talk to some of these people,
it’s the administration who actually wants them to do that case.
So it’s very complex.
Dr David M. Follette (Sacramento, Calif). I’ve been on a num-
ber of credentialing committees. The problem is that when they
credential general surgeons, they look at their training and then74 The Journal of Thoracic and Cardiovascular Surgethey compare their numbers to the numbers that the American
Board of Thoracic Surgery requires. For example, a number of
years ago, the Board required 20 lobectomies. If a general surgeon
documented 20 lobectomies, the credentials committees were in
a very difficult position to deny them privileges. So the question
is, in your regional system, how do you think you could get around
this?
Dr Freeman. And that may work in our favor now. As most of
you know, the general surgical residency training has changed
significantly since most of us were general surgeons. Where
senior level residents did a lot of noncardiac thoracic surgery,
a lot of that has gone away; the requirements are much lower,
and I think most general surgeons now come out with much
less experience than they did 20 years ago in noncardiac
thoracic surgery, unless they are very interested, at least in my
experience.
Dr Stephen D. Cassivi (Rochester, Minn). Richard, I congratu-
late you. I think this is going to be an oft-quoted paper. Clearly,
you’re preaching to the converted here, and this is a message
that needs to go beyond this room.
The argument countering your findings will be that you’re
a general thoracic surgeon and you’re going to be biased. I just
wanted to emphasize that I think you have bent over backwards
to be fair in the construction of your comparison. You have com-
pared open lobectomy with open lobectomy, whereas, as we know
that video-assisted thoracoscopic surgical lobectomies are grow-
ing in number and are much more likely within the population
of general thoracic surgeons. So your length of stay, your comor-
bidities, and your cost would likely show an even at a greater dis-
parity if you were to compare general thoracic surgeons with
general surgeons. It’s more of a comment than a question, but I
think it’s something that we all need to underline as we go
forward with these new data. Thanks very much for your
presentation.
Dr Freeman. I think that’s an excellent point.ry c January 2013
